COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,886 Articles (22,568 medRxiv, 8,318 bioRxiv)

Most recent first Previous |  Page 1698: Articles 16971-16980  | Next

SARS-CoV-2 evolution in animals suggests mechanisms for rapid variant selection
Bashor, L., Gagne, R. B., Bosco-Lauth, A., Bowen, R., Stenglein, M., VandeWoude, S.
10.1101/2021.03.05.434135 — Posted: 2021-03-08
Human nasal and lung tissues infected ex vivo with SARS-CoV-2 provide insights into differential tissue-specific and virus-specific innate immune responses in the upper and lower respiratory tract
Alfi, O., Yakirevich, A., Wald, O., Wandel, O., Izhar, U., Oiknine-Djian, E., Nevo, Y., Elgavish, S., Dagan, E., Madgar, O., Feinmesser, G., Pikarsky, E., Bronstein, M., Vorontsov, O., Jonas, W., Ives, J., Walter, J., Zakay-Rones, Z., Oberbaum, M., Panet, A., Wolf, D. G.
10.1101/2021.03.08.434404 — Posted: 2021-03-08
A comparative recombination analysis of human coronaviruses and implications for the SARS-CoV-2 pandemic
Pollett, S., Conte, M. A., Sanborn, M. A., Jarman, R. G., Lidl, G. M., Modjarrad, K., Maljkovic Berry, I.
10.1101/2021.03.07.434287 — Posted: 2021-03-08
Experimental susceptibility of North American raccoons (Procyon lotor) and striped skunks (Mephitis mephitis) to SARS-CoV-2
Francisco, R., Hernandez, S. M., Mead, D. G., Adcock, K. G., Burke, S. C., Nemeth, N. M., Yabsley, M. J.
10.1101/2021.03.06.434226 — Posted: 2021-03-08
Pediatric nasal epithelial cells are less permissive to SARS-CoV-2 replication compared to adult cells
Zhu, Y., Chew, K. Y., Karawita, A. C., Yamamoto, A., Labzin, L. L., Yarlagadda, T., Khromykh, A. A., Stocks, C. J., Xia, Y., Kollmann, T. R., Martino, D., Kicic, A., Bielefeldt-Ohmann, H., Bowen, A. C., Sly, P. D., Spann, K. M., Short, K. R.
10.1101/2021.03.08.434300 — Posted: 2021-03-08 Discussion: Onsite
Drug development of an affinity enhanced, broadly neutralizing heavy chain only antibody that restricts SARS-CoV-2 in hamsters
Schepens, B., van Schie, L., Nerinckx, W., Roose, K., Van Breedam, W., Fijalkowska, D., Devos, S., Weyts, W., De Cae, S., Vanmarcke, S., Lonigro, C., Eeckhaut, H., Van Herpe, D., Borloo, J., Oliveira, A. F., Catani, J. P., Creytens, S., De Vlieger, D., Michielsen, G., Marchan, J. C. Z., Moschonas, G. D., Rossey, I., Sedeyn, K., Van Hecke, A., Zhang, X., Langendries, L., Jacobs, S., ter Horst, S., Seldeslachts, L., Liesenborghs, L., Boudewijns, R., Tibaut, H. J., Dallmeier, K., Vande Velde, G., Weynand, B., Beer, J., Schnepf, D., Ohnemus, A., Foo, C. S.-Y., Abdelnabi, R., Maes, P., Kaptein, S. J. F., Rochapereira, J., Jochmans, D., Delang, L., Peelman, F., Staeheli, P., Schwemmle, M., Tersago, D., Germano, M., Heads, J., Henry, A., Popplewell, A., Ellis, M., Brady, K., Turner, A., Dombrecht, B., Stortelers, C., Neyts, J., Callewaert, N., Saelens, X.
10.1101/2021.03.08.433449 — Posted: 2021-03-08
Deletion disrupts a conserved antibody epitope in a SARS-CoV-2 variant of concern
Rennick, L. L., Robinson-McCarthy, L. R., Nambulli, S., Duprex, W. P., McCarthy, K. R.
10.1101/2021.03.05.434168 — Posted: 2021-03-08
Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies
Muecksch, F., Weisblum, Y., Barnes, C., Schmidt, F., Schaefer-Babajew, D., Lorenzi, J., Flyak, A., DeLaitsch, A., Huey-Tubman, K., Hou, S., Schiffer, C., Gaebler, C., Wang, Z., Da Silva, J., Poston, D., Finkin, S., Cho, A., Cipolla, M., Oliveira, T., Millard, K., Ramos, V., Gazumyan, A., Rutkowska, M., Caskey, M., Nussenzweig, M., Bjorkman, P., Hatziioannou, T., Bieniasz, P.
10.1101/2021.03.07.434227 — Posted: 2021-03-08 Discussion: Onsite
Development and pre-clinical evaluation of Newcastle disease virus-vectored SARS-CoV-2 intranasal vaccine candidate
Fernandez-Diaz, M., Calderon, K., Rojas-Neyra, A., Vakharia, V. N., Choque-Guevara, R., Montalvan, A., Poma-Acevedo, A., Rios-Matos, D., Agurto-Arteaga, A., Cauti-Mendoza, M. D. G., Perez-Martinez, N., Isasi-Rivas, G., Tataje-Lavanda, L., Palomino, M., Bailon, H., Sernaque-Aguilar, Y., Ygnacio-Aguire, F., Criollo-Orozco, M., Huaccachi-Gonzalez, E., Delgado-Ccancce, E., Villanueva-Perez, D., Montesinos-Millan, R., Gutierrez-Manchay, K., Pauyac-Antezana, K., Ramirez-Ortiz, I., Quinones Garcia, M. S., Cauna-Orocollo, Y., Vallejos-Sanchez, K., Rios-Angulo, A. A., Nunez-Fernandez, D., Salguedo-Bohorquez, M. I., Ticona, J., Fernandez-Sanchez, M., Garcia, P., Icochea, E., Guevara, L., Zimic, M., COVID-19 Working Group in Peru
10.1101/2021.03.07.434276 — Posted: 2021-03-08 Discussion: Onsite
Knowledge, Attitude and Practices towards COVID-19 Guidelines among Students in Bangladesh
Kumar, B., Pinky, S. D., Nurudden, A. M.
10.1101/2021.03.07.433083 — Posted: 2021-03-08

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).